Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice

Tao Hua, Chen Chang, Xuehua Zhang, Yuqing Huang, Haiyan Wang, Dao Hua Zhang, Bo TangFrontiers in Microbiology 2022 · DOI

This study, published in Frontiers in Microbiology, explores a novel intranasal vaccine strategy for Pseudorabies virus (PRV). By combining a mucoadhesive polymer adjuvant (Gel 01) with a multi-component immune stimulant (CVCVA5), researchers achieved a synergistic effect that significantly enhanced both mucosal and systemic immunity in mice, providing complete protection against lethal viral challenges.

TL;DR

Researchers developed a potent intranasal vaccine for Pseudorabies virus by combining two distinct adjuvants (Gel 01 and CVCVA5) with an inactivated virus. This "combination adjuvant" approach successfully triggered robust mucosal IgA and systemic T-cell memory, resulting in 100% survival in mice against high-dose viral challenges where single-adjuvant formulations failed.

What Problem Does This Paper Address?

Pseudorabies virus (PRV) is a highly contagious herpesvirus that devastates the swine industry and poses a zoonotic threat to other mammals, including humans. Since 2011, highly virulent mutant strains have emerged in China, rendering the classical Bartha-K61 vaccine insufficient.

Because PRV primarily infects via the respiratory tract, intranasal vaccines are an ideal first line of defense. However, inactivated (killed) vaccines—which are safer than live-attenuated ones—often struggle with low immunogenicity when delivered nasally. The "residence time" in the nasal cavity is short, and the immune system often ignores the naked antigen. The challenge is finding an adjuvant system that can both keep the vaccine in place and sound the alarm for a robust immune response.

Methods

The researchers used an inactivated PRV strain (SQ) and tested a combination adjuvant system:

  • MONTANIDE™ Gel 01: A mucoadhesive sodium polyacrylate polymer designed to increase the residence time of the antigen on the mucosal surface.
  • CVCVA5 (VA5): A complex adjuvant containing ligands for pattern recognition receptors, including poly I:C (TLR3 ligand), muramyl dipeptide (NOD2 ligand), and levamisole (an immune enhancer).

They immunized BALB/c mice intranasally with various formulations: PBS (control), naked antigen, antigen + Gel 01, antigen + VA5, and antigen + the combination (Gel 01 + VA5). They then measured antibody titers (ELISA), cytokine production, and T-cell memory subsets in the Nasal-Associated Lymphoid Tissue (NALT) using flow cytometry.

Datasets

The study relied on primary experimental data from:

  • Animal Models: 150 healthy female BALB/c mice.
  • Viral Strains: PRV strain SQ, a variant isolated from a pig farm in Jiangsu Province, China.
  • Comparative Benchmarks: The study compared the combination adjuvant against single-adjuvant formulations (Gel 01 alone or VA5 alone) to prove synergy.

Key Insights and Ideas

  • The Power of Synergy: The "aha moment" was the clear synergistic effect. Gel 01 acts as the "delivery truck," sticking the vaccine to the nasal mucosa, while VA5 acts as the "alarm system," activating multiple immune pathways (TLR3 and NOD2). Neither worked nearly as well in isolation.
  • Local Memory Matters: The researchers focused on the NALT, the "brain" of the nasal immune system. They found that the combination adjuvant significantly increased both central memory (CD62L⁺CD44⁺) and effector memory (CD62L⁻CD44⁺) T-cells locally. This suggests the vaccine creates a dedicated "garrison" of immune cells at the exact site where the virus tries to enter.
  • Balanced Th1/Th2 Response: The vaccine didn't just trigger antibodies (Th2); it also stimulated strong cellular immunity (Th1), evidenced by high levels of IFN-γ. This dual-pronged attack is critical for clearing complex herpesviruses.

Key Results

  • Antibody Response: The combination group (Group E) showed significantly higher serum IgG and mucosal IgA (in both lung and nasal washes) compared to all other groups ($p < 0.001$).
  • Cytokine Production: Splenocytes from the combination group produced 4.29-fold more IFN-γ and 2.18-fold more IL-4 than the naked antigen group.
  • Survival Rates: In a high-dose challenge (100 × LD₅₀ of virulent PRV):
  • Combination Adjuvant: 100% survival.
  • VA5 alone: 50% survival.
  • Gel 01 alone: 40% survival.
  • Naked Antigen: 30% survival.
  • Control (PBS): 0% survival.

Limitations and Future Work

  • Species Translation: While mice are standard models for PRV, they are not the natural host. The vaccine must be tested in pigs to confirm that the NALT response translates to the porcine immune system.
  • Long-term Durability: The study tracked immunity up to 42 days post-immunization. Future research needs to determine how long this mucosal protection lasts (e.g., 6 months to a year).
  • Mechanism Refinement: While the synergy is evident, the specific molecular interactions between the polyacrylate particles of Gel 01 and the TLR/NOD ligands in VA5 remain to be fully characterized.

Summary updated

Abstract

Pseudorabies virus (PRV) not only causes great economic loss to the pig industry but also seriously threatens the biosafety of other mammals, including humans. Since 2011, PRV mutant strains have emerged widely in China, and the classical Bartha-K61 vaccine cannot confer complete protection for pigs. PRV mainly infects pigs <i>via</i> the respiratory tract. Intranasal immunization with PRV has received more attention because intranasal vaccination elicits systemic and mucosal immune responses. To induce systemic and mucosal immune responses against PRV, we developed a combination adjuvant as a delivery system for intranasal vaccine, which was formulated with MONTANIDE™ Gel 01 and CVCVA5. In comparison to naked antigen of inactivated PRV, single Gel 01 adjuvanted inactivated antigen and single CVCVA5 adjuvanted inactivated antigen, intranasal inactivated PRV vaccine formulated with the combination adjuvant induced greater mucosal IgA immunity and serum antibody responses (IgG, IgG1, and IgG2a). Furthermore, the production of the Th1-type cytokine IFN-γ and the Th2-type cytokine IL-4 indicated that the cellular and humoral responses to the intranasal vaccine were improved by the combination adjuvant. In addition, the intranasal vaccine formulated with the combination adjuvant induced long-term T lymphocyte memory with increased central (CD62L<sup>+</sup>CD44<sup>+</sup>) and effector (CD62L<sup>-</sup>CD44<sup>+</sup>) memory subsets of both CD4 and CD8 T cells in nasal-associated lymphoid tissue. Intranasal challenge with virulent PRV in mice showed that the protective efficacy of the intranasal PRV vaccine was improved by the combination adjuvant compared with the other single-adjuvanted vaccines. In summary, these data demonstrated that Gel 01 combined with the CVCVA5 adjuvant induced a synergistic effect to improve mucosal immunity and protective efficacy of the intranasally inactivated PRV vaccine in mice. It represents a promising vaccination approach against PRV infection.
BibTeX
@inproceedings{hua2022protective,
  author = {Tao Hua and Chen Chang and Xuehua Zhang and Yuqing Huang and Haiyan Wang and Dao Hua Zhang and Bo Tang},
  title = {{Protective efficacy of intranasal inactivated pseudorabies vaccine is improved by combination adjuvant in mice}},
  booktitle = {Frontiers in Microbiology},
  year = {2022},
  doi = {10.3389/fmicb.2022.976220},
}
Figure